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Background: Nicorandil, as a selective potassium channel opener, has dual action including coronary and
peripheral vasodilatation and cardioprotective effect through ischemic preconditioning. Considering those
characteristics, nicorandil was suggested to reduce the degree of microvascular dysfunction.
Methods: Thirty-two patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary
intervention (pPCI) were included in the study. Index of microvascular resistance (IMR) was measured in all patients
immediatelly after pPCI before the after administration of Nicorandil. ST segment resolution was monitored before
intervention and 60 min after terminating the procedure. Echocardiographic evaluation of myocardial function and
transthoracic Doppler derived Coronary flow reserve (CFR) of infarct related artery (IRA) was performed during
hospitalization and 3 months later.
Results: IMR was significantly lower after administration of Nicorandil (9.9 ± 3.7 vs. 14.1 ± 5.1, p < 0.001). There was
significant difference in ST segment elevation before and after primary PCI with administration of Nicorandil (6.9 ±
3.7 mm vs. 1.6 ± 1.6 mm, p < 0.001). Transthoracic Doppler CFR measurement improved after 3 months (2.69 ± 0.38 vs.
2.92 ± 0.54, p = 0.021), as well as WMSI (1.14 ± 0.17 vs. 1.07 ± 0.09, p = 0.004).
Conclusion: Intracoronary Nicorandil administration after primary PCI significantly decreases IMR, resulting in improved
CFR and ventricular function in patients with STEMI undergoing primary PCI.
Keywords: STEMI, Primary PCI, Nicorandil, Microvascular dysfunction, Index of microvascular resistance, Transthoracic
Doppler derived coronary flow reserveIntroduction
In patients with ST segment elevation myocardial infarction
(STEMI) undergoing primary percutaneous coronary inter-
vention (pPCI), despite early reperfusion and achievement
of epicardial coronary artery patency, some patients still ex-
hibit reduced or no coronary flow to distal microcircula-
tion. This complication is not naïve, as it has been shown
that patients with no-reflow phenomenon have worse myo-
cardial function and prognosis in the long term follow-up
[1, 2]. The mechanism of microcirculatory dysfunction is* Correspondence: jesikakostic@yahoo.com
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unless otherwise stated.multifactorial with vasospasm of microcirculation in the
center of different pathophysiological mechanisms [3].
Thus, several treatment options including nitroprusside,
adenosine and verapamile, that all induce vasodilatation
have been proposed to deal with reduced or no coronary
flow [4–8].
Nicorandil is a nicotinamide ester with the dual mech-
anism of action, combining activation of ATP-sensitive
potassium (K-ATP) channels with nitro-vasodilator (nitric
oxide donor) actions. By selective activation of the K-ATP
channels at the sacrolemmal and mitochondrial level,
nicorandil induces coronary and peripheral vasodilatation,
with subsequent reduction of preload and afterload. The
role of the K-ATP channels in ischemic preconditioningThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Considering those mechanisms of action, it has been shown
previously that nicorandil might have an important role in
the treatment of no re-flow following pPCI in acute myo-
cardial infarction [10]. In fact, nicorandil was suggested to
reduce the degree of microvascular dysfunction [11, 12].
The aim of this study was to evaluate the effects of nicor-
andil on microcirculatory function as evaluated by the
index of microcirculatory resistance. In addition, it was of
particular clinical importance to evaluate the effects of
nicorandil on the improvement of ECG ST segment
changes, coronary flow reserve (CFR) and myocardial func-
tion by evaluating wall motion score index (WMSI).
Methods
Study population
The study was designed as a single center prospective
study. Thirty-two patients (mean age 56.5 ± 9.0 years, male
26, and female 6 patients) with ST segment elevation myo-
cardial infarction (STEMI) were enrolled in the study. All
patients were treated according to current recommenda-
tions for STEMI treatment [13], and Nicorandil was admin-
istered in a “top-of-the-treatment” manner after primary
PCI. The diagnosis of STEMI was made according to chest
pain lasting for more than 20 min and ST segment eleva-
tion of more than 2 mm in at least two contiguous leads,
further confirmed by an increase in cardiospecific enzymes.
Immediately after diagnosis was made, the patients were re-
ferred to pPCI with symptoms of STEMI of less than 12 h
of duration, and pretreated before arrival to catheterization
laboratory with clopidogrel 600 mg and aspirin 300 mg.
The study was approved by ethical committee of Medical
faculty, University of Belgrade, Belgrade, Serbia.
Study protocol
All patients presented to catheterization laboratory as
Killip Class I or II. Before starting pPCI of the culprit ar-
tery, all patients received intravenous heparin (70 IU/kg
body mass). PPCI was performed in the usual manner.
Balloon predilatation, thromboaspiration (6 or 7 F Export
aspiration catheter, Medtronic, USA) as well as adminis-
tration of glycoprotein IIb/IIIa inhibitors were performed
or administered when needed according to operator’s
decision.
Measurements of index of microcirculatory resistance
(IMR) were performed after successful PCI by the Radia-
nalyzer™Xpress measurement system (St. Jude Medical,
Minneapolis, Minnesota) with the pressure wire (Certus,
St. Jude Medical, USA) positioned in the distal part of the
culprit coronary artery. After measurement of the resting
transit times with injection of 3–4 mL of saline three
times intracoronary, maximal hyperemia was induced by
intracoronary bolus of papaverine (15 mg for left coronary
artery or 10 mg for right coronary artery), and hyperemicmean transit times were obtained by repeated injections of
intracoronary saline for three times (3–4 mL per time).
Then, 12 mg of Nicorandil was administered intracoron-
ary, and the same IMR measurements were repeated
10 min later. IMR was calculated by multiplying distal
pressure by hyperemic mean transit time.
ECG ST segment elevation [14] was analyzed at base-
line (before primary PCI) and 60 min after the end of
the procedure, and the difference between basal and post
PCI ST segment elevation was calculated. Thrombolysis
in Myocardial Infarction (TIMI) flow grade [15] and
Myocardial Blush Grade (MBG) [16] were analyzed be-
fore pPCI in all patients, and after Nicorandil adminis-
tration. Two cardiologists who were not aware of the
clinical data of the patients evaluated ST-elevation, TIMI
and MBG score.
Evaluation of global left ventricular function and coronary
flow reserve
Transthoracic echocardiogram (Acuson Sequoia C256,
Siemens Medical Solutions USA) was performed on the
day after pPCI with evaluation of myocardial function
and coronary flow reserve. A 17-segment model was
used to determine systolic left ventricular (LV) function
[17] by wall motion score index (WMSI) that was calcu-
lated by dividing the sum of individual visualized seg-
ment scores by the number of visualized segments.
Transthoracic Doppler echocardiographic examination
was performed with the commercially available digital
ultrasound system (Sequoia C256 Acuson Siemens Moun-
tain View, California) with 3V2C mutifrequency trans-
ducer using second harmonic technology. After standard
examination, distal left anterior descending artery or
postero-descedant branch of right coronary artery was
evaluated with 4 MHz transducer. For visualization of the
flow in the coronary artery was used color Doppler
matched Nyquist limit of 16–30 cm / s, while the flow rate
is measured by pulsed Doppler. For the evaluation of flow
in the distal part of the left anterior descending artery was
used the modified apical three cavities with acoustic win-
dow in the level of midclavicular line in the fourth and
fifth intercostals spaces in the left lateral decubitus pos-
ition. For the assessment of coronary flow in the distal
right coronary artery standard apical longitudinal view
was used. From this position the probe is turned slightly
anti-clockwise and leaned slightly forward, until a coron-
ary flow in last interventricular sulcus using color Doppler
is obtained. The sample pulse Doppler width of 5 mm is
placed on the color signal of a coronary artery in its distal
part. Spectral Doppler signal coronary artery shows a char-
acteristic biphasic appearance with lower systolic and dia-
stolic greater component. A sample volume (3–5 mm
wide) was positioned on the color signal of the distal infarct
related artery. Flow velocity recordings were performed
Table 1 Patients demographic characteristics
Study group (n = 32)
Male gender, n (%) 26 (81.3 %)
Age (years) 56.5 ± 9.0
Hypertension, n (%) 16 (50 %)
Dyslipidemia, n (%) 13 (41 %)
Diabetes
Oral therapy, n (%) 11 (34.4 %)
Insulin therapy, n (%) 1 (3 %)
Smokers
Current, n (%) 16 (50 %)
Ex smokers, n (%) 5 (16 %)
Family history of CAD, n (%) 19 (59.4 %)
Body mass index (kg/m2) 28.8 ± 4.7
Table 2 Clinical, procedural and angiographic data
Study group (n = 32)
Pain to door time, median (IQR) minutes) 161 (134)
Door to balloon time, median (IQR) (minutes) 64 (57)
Total ischemic time, median (IQR) (minutes) 225 (144)
Killip class on admission
Class I 23 (72 %)
Class II 9 (28 %)
Anterior wall MI 13 (40 %)
Infarct related artery system
LAD 13 (40 %)
RCA 19 (60 %)
TIMI flow grade 0 before 31 (97 %)
Manual thromboaspiration 7 (30 %)
Balloon predilatation 15 (47 %)
GP IIb/IIIa inhibitors 3 (10 %)
Number of stents implanted 1.38 ± 0.61
Total stent length (mm) 21.8 ± 4.8
Average stent diameter (mm) 3.14 ± 0.38
Balloon postdilatation 2 (6.3 %)
TIMI flow grade 3 after 32 (100 %)
Myocardial blush grade 3 after 32 (100 %)
Creatine kinase (U/L) 1778 ± 1108
Creatine kinase MB (U/L) 148 ± 116
Troponin (μg/L) 32.3 ± 45.9
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hyperemia, which was induced by administration of intra-
venous adenosine (140 mcg/kg over 2 min). CFR was ob-
tained as the ratio of peak diastolic flow velocity during
vasodilation and diastolic flow velocity at baseline [18, 19].
Follow-up echocardiographic examination with evaluation
of WMSI and CFR was performed 3 months after pPCI.
Statistical analysis
The sample size was calculated using the program
G*Power. In a previous randomized study (QUOTE)
[20], which compared the values of IMR in patients
undergoing PCI in stable coronary artery disease who re-
ceived placebo or Nicorandil. Considering difference be-
tween placebo and Nicorandil (IMR values were 25.4 ±
12.1, and 17.9 ± 9.1), α = 0.05 and the power of the stat-
istical test (1-β) = 0.95, the needed sample size was esti-
mated to include at least 28 patients.
The normality assumption for continuous variables
was evaluated by the KolmogorovSmirnov test. Continu-
ous variables are presented as means and standard devi-
ations for normally distributed variables or as medians
and interquartile ranges (IQR) for non-normal distribu-
tion. They were compared using Students t-test, or its
non-parametric equivalent Mann–Whitney U test. Cat-
egorical variables were presented as counts and percent-
ages and were compared with the chi-square or Fisher’s
exact test. Relation of various numerical and dichotom-
ous variables to IMR was evaluated using Pearson’s’ cor-
relation. Univariable and multivariable linear regression
(stewise model) was used to determine predictors of
IMR and CFR. For all analysis, a two-sided p < 0.05 was
considered statistically significant. All data were proc-
essed using the statistical package for social sciences,
version (SPSS, Chicago, Ill).
Results
Patients demographic and risk profile characteristics are
presented in Table 1. Clinical, procedural and angio-
graphic data are presented in Table 2. PPCI was angio-
graphically successful in all patients with achievement of
TIMI and MBG grade 3 in all patients. Total ischemic
time was 225 (144 IQR) minutes; there were 13 patients
with anterior wall STEMI, and 19 patients with inferior
wall STEMI (13 LAD, 19 RCA). The peak values of car-
diac markers were: CK 1778 ± 1108 U/l, CK MB 148 ±
116 ng/ml, and troponin 32 ± 46 ng/ml.
There was a significant resolution of ST segment ele-
vation after pPCI in comparison to hospital admission
ECG (6.9 ± 4.0 mm vs. 1.6 ± 1.6 mm, p<0.001).
IMR was statistically significantly lower after administra-
tion of Nicorandil in comparison to IMR before Nicoran-
dil administration 14.1 ± 5.1 vs. 9.9 ± 3.7, p < 0.001 (Fig. 1).
Transthoracic Doppler derived CFR (Fig. 2), performedthe day after pPCI was 2.69 ± 0.38, and further signifi-
cantly improved after 3 months to 2.92 ± 0.54, p = 0.021.
WMSI measured one day after pPCI improved from 1.16 ±
0.17 to 1.07 ± 0.09, p = 0.004, after 3 months follow-up.
Figure 3a, b and c demonstrate a patient with acute an-
terior myocardial infarction treated successfully with pPCI
Fig. 1 IMR in infarct related artery before and after Nicorandil administration
Fig. 2 Transthoracic Doppler derived CFR day after and in follow-up
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Fig. 3 Patient with anterior AMI: a pPCI, b IMR after Nicorandil, c CFR in day after pPCI
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2.6, and WMSI 1.12.
There was a correlation between IMR after Nicorandil
administration and WMSI at 3 months follow-up period
(r = 0.376, p = 0.034), as well as between IMR after nicor-
andil administration and noninvasive CFR the day after
primary PCI (r = 0.510, p = 0.003) as well at 3 months
follow-up period (r = 0.437, p = 0.012). Nicorandil ad-
ministration was the only univariate predictor of the
final IMR (p = 0.003). IMR after nicorandil administra-
tion was the only univariate predictor of nonivasive CFR
the day after (p = 0.003) and in the 3 months follow-up
period after primary PCI (p = 0.012).
During the follow-up period of average 1.5 year we had
only one patients with non cardiac related death. There
were no heart failures, re-infarction, re-hospitalisation, re-
intervention or cardiac death.Discussion
The main findings of our study indicate that Nicorandil
improves microvascular function, as presented by lower
index of microvascular resistance and normal CFR im-
mediately one day after pPCI that further improvedafter 3 months, which all translated into improved myo-
cardial function as demonstrated by better WMSI.
Preservation of microvascular integrity, prevention of
inflammatory damage and metabolic support of ischemic
myocardium are important in the prevention and decrease
of vascular-reperfusion injury [3]. The complex pathogen-
esis of microvascular injury: production of oxygen free
radicals, neutrophil activation, endothelial and myocites
swelling, loss of antioxidant enzymes and cardiomyocite
apoptosis [3, 21], urges for new preventive solutions. In
contrast to classic nitrates that have dilator effect on large
conductive vessels (epicardial vessels), Nicorandil has
greater effect on small resistive vessels (arterioles), thus
exhibiting cardioprotective effects [22–24].
IMR is not affected by hemodynamic conditions and
has good correlation with absolute coronary flow and
true microvascular resistance [25], and represents reli-
able parameter for invasive on-site assessment of micro-
circulatory function [26]. In fact, Fearon et al. [27]
demonstrated that IMR is the strongest predictor for
the improvement of left ventricular function, with sig-
nificant correlation with wall motion score index and
peak CK. Finally, it has been demonstrated that high
IMR after primary PCI was associated with higher death
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term follow-up [28].
Some previous studies [29–32] have demonstrated that
Nicorandil with its cardioprotective effect improves micro-
vascular dysfunction, and might be given intravenously be-
fore starting pPCI or as an intracoronary bolus. The impact
of Nicorandil in patients with stable angina was demon-
strated in IONA (Impact Of Nicorandil in Angina) [33]
randomized trial wherein 5126 patients with established
coronary heart disease (previous MI, CABG), or a positive
exercise test already on the optimal antianginal drug ther-
apy, were included. All patients were divided into 2 groups,
treated with Nicorandil or placebo with the follow-up of 1–
6 years. In Nicorandil treated group patients had signifi-
cantly less frequent events like coronary death, non-fatal
MI, and unplanned hospital admission. Ono et al. [34], in
the study with Nicorandil pretreatment (IV bolus 4 mg)
followed by constant infusion at 8 mg/h for 24 h vs. placebo
in patients with acute myocardial infarction undergoing
pPCI, examined nicorandil effect on reactive oxygen species
(ROS) formation by measuring urinary excretion of PGF2α
(8-epi-prostaglandin F2α–specific marker for ROS forma-
tion) and clinical outcome. Nicorandil pretreatment almost
completely inhibited the ROS formation (decrease in urin-
ary excretion of 8-epi-PGFα) resulting in inhibition of no-
reflow phenomenon and improvement in LV function vs.
control group at 6 month after reperfusion therapy. Ishii
et al. [12] performed 5 years follow-up randomized study in
patients with STEMI where Nicorandil was given before
pPCI as intravenous infusion of 12 mg (in 100 ml of saline)
during 20–30 min period. They found that single admission
of Nicorandil improved not only early but also late clinical
events, including cardiovascular death or hospital admis-
sion due to worsening congestive heart failure. Finally, Ito
and al. [35] in 60 patients with STEMI undergoing pPCI
evaluated the effects of Nicorandil (2 mg intracoronary)
and nitroglycerine (250mcg intracoronary) in cross-over
fashion on microvascular function as measured by IMR.
They have demonstrated that Nicorandil reduced micro-
vascular dysfunction after pPCI more effectively than did
nitroglycerine.
Recovery of coronary microvascular function takes
place in the first 24–48 h after primary PCI and is a dy-
namic process. Generally, CFR>2 is taken for the normal
cut-off in the most clinical situations. CFR during ad-
enosine induced hyperemia and diastolic deceleration
time provide prognostic information to standard clinical
and echocardiography data for infarct size prediction
and myocardial functional recovery [19, 36].
These data imply that preservation of coronary micro-
circulatory function after primary PCI in STEMI pa-
tients is important for limitation of the infarct size, and
improvement of prognosis independently from other
factors. Therefore aggressive therapeutic strategy aimedto microcirculation could probably prevent adverse re-
modeling due to large infarction size. Non-invasively
assessed IRA coronary flow reserve and diastolic decel-
eration time on the first and second day after primary
PCI in patients with first STEMI predict final infarct
size, independently of other covariates [37].
Study limitation
This study included rather small number of patients that
was estimated on the basis of sample size calculation for
IMR improvement in patients with stable coronary artery
disease. The follow-up period of 3 months might be short,
but the effects on nicorandil in the treatment group clearly
demonstrated improvement of IMR, CFR and WMSI. The
Nicorandil effects were not compared to the control group
or other drugs that might improve microcirculatory function
due to limited access and specific package of Nicorandil that
precluded proper randomization procedure in patients with
STEMI undergoing pPCI. Transthoracic Doppler echocardi-
ography as a technique could not be considered as a substi-
tute for other dedicated techniques that can directly assess
transmurality of myocardial viability, such as magnetic res-
onance imaging, but could be useful in providing additional
information about coronary pathophysiology and prognosis,
considering the broad availability and low cost of the
method [19].
Conclusion
Intracoronary Nicorandil administration in patients with
STEMI undergoing pPCI significantly improved microvas-
culatory function by decreasing IMR and increasing CFR.
Larger randomized studies are needed to confirm these ef-
fects particularly in comparison to the other drugs that
might improve microcirculatory function.
Clinical implications
Our group of patients consisted of patients with STEMI
undergoing primary PCI with “small to moderate” size
myocardial infarction as expressed by CK, wall motion
score index, as well as IMR. Even in this group of patients
nicorandil produced significant decrease in IMR and im-
provement in microcirculatory function. Thus, it can be
expected that in the subset of patients with large myocar-
dial infarction and real no-reflow phenomenon, nicorandil
might induce most beneficial effects on microcirculatory
and myocardial function.
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